$13.66
-0.50-3.53%
al cierre: Nov 20, 4:00 PM EST
$13.70
0.040.29%
After hour: Nov 20, 4:56 PM EST

The average analyst price target for Mineralys Therapeutics is $45.86, 234.7% above the current price. Of 9 analysts, 7 rate it Buy and 2 Hold. Targets range from $26 to $56. The latest change came on Oct 12, 2026, when UBS initiated coverage of Mineralys Therapeutics with a Neutral rating and a $29 price target.
Price Target Range — 9 Quarters
Analyst Consensus — 9 Analysts
Rating Trend — Last 9 Months